Risk factors for antituberculous chemotherapy‐induced hepatotoxicity in Japanese pediatric patients

Abstract

This study indicated that intensive monitoring of hepatotoxicity should be performed for younger children (<5 years) receiving pyrazinamide for antituberculosis chemotherapy.